U.S. Markets open in 4 hrs 21 mins
  • S&P Futures

    4,533.25
    -42.50 (-0.93%)
     
  • Dow Futures

    34,559.00
    -63.00 (-0.18%)
     
  • Nasdaq Futures

    15,687.50
    -301.00 (-1.88%)
     
  • Russell 2000 Futures

    2,156.20
    -49.00 (-2.22%)
     
  • Crude Oil

    66.22
    -0.28 (-0.42%)
     
  • Gold

    1,782.10
    +21.40 (+1.22%)
     
  • Silver

    22.57
    +0.25 (+1.12%)
     
  • EUR/USD

    1.1317
    +0.0012 (+0.1019%)
     
  • 10-Yr Bond

    1.3430
    -0.1050 (-7.25%)
     
  • Vix

    30.67
    +2.72 (+9.73%)
     
  • GBP/USD

    1.3235
    -0.0067 (-0.5029%)
     
  • USD/JPY

    112.8000
    -0.4090 (-0.3613%)
     
  • BTC-USD

    47,545.09
    -1,447.90 (-2.96%)
     
  • CMC Crypto 200

    1,367.14
    -74.62 (-5.18%)
     
  • FTSE 100

    7,122.32
    -6.89 (-0.10%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     

Recap: Chimerix Q2 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 54.29% year over year to ($0.16), which beat the estimate of ($0.17).

Revenue of $1,402,000 declined by 2.50% from the same period last year, which beat the estimate of $1,060,000.

Outlook

Chimerix hasn't issued any earnings guidance for the time being.

Chimerix hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Aug 10, 2020

View more earnings on CMRX

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/f4xqp47n

Price Action

52-week high: $3.88

52-week low: $1.19

Price action over last quarter: Up 17.41%

Company Overview

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes a treatment for acute myeloid leukemia (or AML) and an antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment--pharmaceuticals.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.